Search Results - %22Life+Science%22+and+%22Drug+Delivery%22

13 Results

Sort By:

Fc-folate conjugate for the treatment of triple negative breast cancer

Approximately 13% of women in the United States will develop breast cancer according to the American Cancer Society. That makes breast cancer the second leading cause of cancer death in women right behind lung cancer. Triple negative breast cancer (TNBC) represents about 10 – 20% of all breast cancers. Triple negative refers to cancer cells...

Published: 12/7/2022 | Inventor(s): Cecilia Speyer

Keywords(s): Anti-cancer, Breast Cancer, Cancer, Cancer Therapies

Category(s): Antibodies, Assays, Biology, Biomedical, Chemical Processing/Synthesis, Diseases, Drug Delivery, Life Science, Oncology, Protein/peptides, Receptors/targets, Small molecule, Therapeutics

Using nanotechnology to target aggressive cancers with a novel small molecule inhibitor of the DNA damage tolerance pathway

Background: Nanotechnology is emerging as a promising tool to target cancer cells. Gold nanoparticles (GNPs) are preferentially taken up by cancer cells when injected into the blood stream and their safety has been demonstrated in human clinical trials. WSU researchers have designed a unique nanoparticle conjugate that combines a GNP with a small molecule...

Published: 8/29/2018 | Inventor(s): Malathy Shekhar, Guangzhao Mao, Yanhua Zhang

Keywords(s):

Category(s): Life Science, Oncology, Small molecule, Receptors/targets, Nano-based, Drug Delivery, Therapeutics, Diseases

An in vivo QQ-systemic protein delivery technology and applications

BackgroundThis invention contains a new composition of our researchers’ previously patented QQ-protein delivery technology and the in vivo applications of this protein delivery technology via systemic administered proteins for cancer diagnosis and therapy. Many proteins and peptides are used as highly specific and effective therapeutic agents....

Published: 11/9/2021 | Inventor(s): Jianjun Wang, Qianqian Li, Quan Jiang, Feng Jiang, Michael Chopp

Keywords(s): Cancer Therapies, Drug Delivery

Category(s): Diagnostics, Drug Delivery, Life Science, Oncology, Research tools, Therapeutics

A protein-induced In situ cell-conversion technology and applications

BackgroundCell reprogramming and trans-differentiation are techniques that convert somatic cells of individuals into either stem cells, including embryonic and adult stem cells (reprogramming) or the other type of somatic cells (trans-differentiation). These techniques are usually performed in the cell culture settings using viral gene delivery and...

Published: 11/9/2021 | Inventor(s): Jianjun Wang, Qianqian Li, Feng Jiang, Michael Chopp, Guojun Wu

Keywords(s): Cancer Therapies, Drug Delivery

Category(s): Drug Delivery, Life Science, Research tools, Oncology

Generation of gp78 null mice

Generation of gp78 null mice WSU Tech#: 15-1291 Technology: Generation of the first preclinical experimental model system for gp78-/- C57BL/6 mice, which spontaneously develops age-related nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC), linking endoplasmic reticulum-associated degradation (ERAD) to hepatosteatosis, cirrhosis,...

Published: 11/22/2021 | Inventor(s): Avraham Raz, Andrei Golovko

Keywords(s):

Category(s): Animal models, Biology, Biomedical, Biotechnology, Drug Delivery, Drug Discovery, Drug Screening, Genomics/Genetics, Life Science, Oncology, Research tools

Targeted Drug Delivery for Spinal Cord Injury

Technology Summary: WSU researchers have developed a new nanoparticle-drug conjugate for treating cervical spinal cord injury (SCI) that can restore respiratory function to the paralyzed hemi diaphragm. Using the nano-conjugate enables targeted delivery of the drug directly to the respiratory centers resulting in dramatically lower effective dosages...

Published: 11/11/2021 | Inventor(s): Harry Goshgarian, Guangzhao Mao, Yi Zou, Sunxi Wang

Keywords(s): Central Nervous System, Drug Delivery, Neuroscience, Therapeutics

Category(s): Therapeutics, Life Science, Drug Delivery, Medical, Chemical Processing/Systhesis, Nanomaterials, Neurological disorders, Receptors/targets

Ruthenium-based caging of nitrile-containing enzyme inhibitors

Technology Summary: Novel synthesis methods for caging nitrile-containing bioactive molecules to a non-toxic ruthenium metal complex have been developed which enable light activated release of a cathespin K inhibitor. Numerous potent and selective cathepsin inhibitors are being developed as drug candidates. Cysteine cathepsins are involved in the pathophysiology...

Published: 10/27/2023 | Inventor(s): Jeremy Kodanko, Claudia Turro

Keywords(s): Cancer, Pharmaceuticals

Category(s): Chemicals, Drug Delivery, Life Science, Physical Sciences, Other

Nanoparticle Method to Stabilize Suspension-Based pMDI HFA Formulations

Novel nanoparticle-based drug compositions and methods that improve and expand therapeutic drug delivery to the lungs through pressurized meter-dose inhalers (pMDIs). A large variety of approaches have been developed at WSU aimed at improving the aerosol characteristics and expanding the range of target species deliverable. These improved formulations...

Published: 11/11/2021 | Inventor(s): Sandro Da Rocha, Libo Wu

Keywords(s): Asthma, Drug Delivery, Formulation, Nanomaterials, Pharmaceuticals

Category(s): Drug Delivery, Life Science, Nano-based, Therapeutics

Dual action nanocarrier combining CXCR4 antagonist and polyplex gene delivery for treatment of metastatic cancer and other diseases

Novel bio-reducible polymer compositions which combine the ability to act as a CXCR4 antagonist and simultaneously provide enhanced gene delivery through the formation of inert nanocarrier polyplexes have been developed. As would be expected for biodegradable polymers, the cytotoxicity of these nanocarrier compositions are very low with measured IC50...

Published: 11/11/2021 | Inventor(s): David Oupicky, Jing Li

Keywords(s): Cancer, Cancer Therapies, Compound, Drug Delivery, Drug Target, Formulation, Imaging, Nanomaterials, Pharmaceuticals, Therapeutics

Category(s): Drug Delivery, Gene Therapy, Therapeutics, Life Science, Oncology, Nano-based, Metabolic disorders, Biologicals

GlyB4 Fusion with Neuregulin Heparin-Targeting Domain to Block Neuregulin Signaling

We have harnessed this natural targeting ability of NRG by fusing the HBD of NRG to soluble HER4. This fusion protein retains high affinity heparin binding to heparin and to cells that express heparan sulfates resulting in a more potent NRG antagonist. In vivo, it is targeted to peripheral nerve segments where it blocks the activity of NRG as a Schwann...

Published: 12/6/2022 | Inventor(s): Jeffrey Loeb, Qunfang Lee

Keywords(s): Anti-cancer, Biotechnology, Cancer risk, Cancer Therapies, Drug Delivery, Drug Target, Epilepsy

Category(s): Life Science, Drug Delivery, Other

1 2